Galera Therapeutics, INC Form 4 insider transactions

Mel Sorensen, President and CEO and a Director of Galera Therapeutics, Inc., reported multiple transactions in common stock on August 3, 2026.

Kevin G Lokay, a Director of Galera Therapeutics, Inc., reported a transaction in 240 shares of common stock on August 3, 2026.

Nancy T Chang, a Director and 10% owner of Galera Therapeutics, Inc., reported multiple transactions in common stock on May 15, 2026.

Lawrence M Alleva, a Director of Galera Therapeutics, Inc., reported multiple transactions in common stock on August 3, 2026.

Joel F. Sussman, Chief Accounting Officer of Galera Therapeutics, Inc., reported a transaction in 10,000 shares of common stock on August 3, 2026.

Michael R. Friedman, a Director of Galera Therapeutics, Inc., reported multiple transactions in common stock on May 15, 2026.

Galera Therapeutics and Obsidian Therapeutics announce a merger, with Obsidian's OBX-115 TIL therapy showing promising efficacy in advanced melanoma.

Galera Therapeutics and Obsidian Therapeutics have entered into an Agreement and Plan of Merger, with Galera merging into a subsidiary of a newly formed parent company.

Emerald Bioventures, LLC converted 20,813.8186 shares of Series B Preferred Stock into 20,813,818 shares of Galera Therapeutics common stock.

Obsidian Therapeutics announced positive Phase 2 clinical results for its lead TIL cell therapy candidate, OBX-115, in patients with advanced melanoma.

Obsidian Therapeutics announced an oral presentation of Phase 2 clinical data for its OBX-115 therapy in advanced melanoma at the 2026 ASCO Annual Meeting.

Galera Therapeutics and Obsidian Therapeutics have entered into a merger agreement to combine their businesses, creating a new entity with a focus on advancing their respective pipelines.

Obsidian Therapeutics and Galera Therapeutics have entered into a merger agreement, concurrent with a $350 million PIPE financing, to advance Obsidian's cell therapy development.

Obsidian Therapeutics announced plans to merge with Galera Therapeutics and list on Nasdaq, securing $350 million in private financing to advance its cell therapies.

Galera Therapeutics and Obsidian Therapeutics have announced a proposed merger, with details filed with the SEC, outlining the path forward for a newly-formed company.

Galera Therapeutics and Obsidian Therapeutics have entered into a definitive merger agreement, combining their operations and advancing Obsidian's TIL cell therapy pipeline.

Michael R. Friedman, a Director at Galera Therapeutics, Inc., has converted Series B Preferred Stock into Common Stock, increasing his beneficial ownership.

Nancy T. Chang, a Director and 10% owner of Galera Therapeutics, Inc., converted a portion of her Series B Preferred Stock into Common Stock on April 7, 2026.

Galera Therapeutics' President and CEO, J. Mel Sorensen, sold 70,000 shares of common stock on November 20, 2025, under a Rule 10b5-1 plan.

Joel F. Sussman, Chief Accounting Officer of Galera Therapeutics, Inc., acquired 2,000,000 stock options on May 1, 2025.

Galera Therapeutics' CEO, Mel Sorensen, received 6,000,000 stock options on May 1, 2025, according to a Form 4 filing with the SEC.

Director Kevin G. Lokay of Galera Therapeutics, Inc. acquired 48,000 stock options on February 24, 2025.

Director Michael Friedman of Galera Therapeutics, Inc. [GRTX] acquired 96,000 stock options on February 24, 2025, according to a Form 4 filing with the SEC.

Director Nancy T. Chang acquired 96,000 stock options in Galera Therapeutics, Inc. on February 24, 2025.

Lawrence M. Alleva, a director of Galera Therapeutics, acquired stock options for 48,000 shares on February 24, 2025.

Nancy T. Chang, a director and 10% owner of Galera Therapeutics, reports changes in beneficial ownership following the acquisition of Nova Pharmaceuticals.

Michael Friedman, a director of Galera Therapeutics, acquired Series B Preferred Stock as a result of the merger with Nova Pharmaceuticals on December 30, 2024.

Galera Therapeutics CEO, J. Mel Sorensen, disposed of 67,015 shares of common stock at a price of $0.072 per share on August 16, 2024.

Galera Therapeutics' board approves a plan to dissolve the company and liquidate assets after failing to find suitable strategic alternatives, with a stockholder vote scheduled for October 17, 2024.

Yair Schneid, a director of Galera Therapeutics, has significantly increased his holdings in the company through a series of open market purchases in April 2024.